Gossamer Bio, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six months ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(29,764) | $(74,911) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 9 | 12 |
| Stock-based compensation expense | 8,767 | 4,991 |
| Amortization of operating lease right-of-use assets | 475 | 543 |
| Amortization and expense of debt discount and issuance costs | 5,210 | 486 |
| Amortization of premium on marketable securities, net of accretion of discounts | (1,052) | (4,611) |
| Change in warrant liability | (1,602) | — |
| Change in derivative liability | (4,113) | — |
| Gain on debt extinguishment | (43,846) | — |
| Changes in operating assets and liabilities: | ||
| Receivable from contracts with collaborators | 6,122 | (2,241) |
| Prepaid expenses and other current assets | 8,891 | (5,369) |
| Other assets | (21) | (100) |
| Operating lease liabilities | (475) | (534) |
| Accounts payable | 1,565 | (6,774) |
| Accrued expenses and other current liabilities | (1,397) | 363 |
| Accrued research and development expenses | (11,982) | 5,146 |
| Accrued compensation and benefits | (2,151) | (2,834) |
| Contract liabilities | (12,370) | (952) |
| Accrued interest expense | (411) | — |
| Net cash used in operating activities | (78,145) | (86,785) |
| Cash flows from investing activities | ||
| Purchase of marketable securities | (24,994) | (176,533) |
| Maturities of marketable securities | 109,300 | 242,800 |
| Purchase of property and equipment | — | (79) |
| Net cash provided by investing activities | 84,306 | 66,188 |
| Cash flows from financing activities | ||
| Payment of debt issuance costs in connection with the exchange of the 2027 Notes | (1,963) | — |
| Payment of equity issuance costs in connection with the exchange of the 2027 Notes | (1,181) | — |
| Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plan | 292 | 372 |
| Proceeds from the exercise of stock options | 220 | 226 |
| Net cash provided by (used in) financing activities | (2,632) | 598 |
| Effect of exchange rate changes on cash and cash equivalents | (113) | 234 |
| Net increase (decrease) in cash and cash equivalents | 3,416 | (19,765) |
| Cash and cash equivalents, at the beginning of the period | 37,732 | 46,074 |
| Cash and cash equivalents, at the end of the period | $41,148 | $26,309 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $5,075 | $5,000 |
| Six months ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Unpaid debt issuance costs in connection with the exchange of the 2027 Notes | $3,631 | $— |
| Unpaid equity issuance costs in connection with the exchange of the 2027 Notes | $2,184 | $— |
| Issuance of common stock in connection with the exchange of 2027 Notes | $45,239 | $— |
| Issuance of a derivative in connection with the exchange of 2027 Notes | $47,051 | $— |
| Issuance of prefunded warrants in connection with the exchange of 2027 Notes | $5,935 | $— |
| Issuance of purchase warrants in connection with the exchange of 2027 Notes | $19,893 | $— |
| Issuance of 2030 Notes in connection with the exchange of 2027 Notes | $18,123 | $— |
| Change in unrealized loss on marketable securities, net | $(68) | $(179) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.